Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
466. |
ECCT/13/04/04 | Enteric Study A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens with Loperamide for Treatment of Ambulatory Watery Travelers’ Diarrhea, and Azithromycin with and without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea |
Principal Investigator(s) 1. CPT Brook A. Danboise Site(s) in Kenya British Army Training Unit, Kenya (BATUK) |
View |
467. |
ECCT/11/10/01 | A RANDOMIZED PHASE IIA TRIAL OF GEMCITABINE COMPARED WITH BLEOMYCIN PLUS VINCRISTINE FOR TREATMENT OF KAPOSI’S SARCOMA IN PATIENTS ON COMBINATION ANTIRETROVIRAL THERAPY IN WESTERN KENYA. |
Principal Investigator(s) 1. NAFTALI WISINDI BUSAKHALA Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH SITE |
View |
468. |
ECCT/12/04/02 | Short-course RPT/INH for latent TB in HIV-infected individuals A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
469. |
ECCT/11/08/05 | Rifapentine During Intensive Phase TB Treatment Evaluation of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis |
Principal Investigator(s) 1. Lena Matata 2. Kevin Cain Site(s) in Kenya KEMRI/CDC-KISUMU |
View |
470. |
ECCT/08/27/12 | MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection. Protocol No. 110021 - MAL 55 STUDY A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa” |
Principal Investigator(s) 1. Dr. Mary Hamel 2. Dr. Patricia Njuguna 3. Dr. Walter Otieno Site(s) in Kenya 1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county) 2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county) 3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county) |
View |